DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years Châtillon, France, December 16, 2025 DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years VITESSE met its primary endpoint: the lower bound of the 95% confidence interval (CI) of the difference between treatment arms was 24.5%, exceeding the prespecified threshold of 15% 46.6% of children treated with the VIASKIN® Peanut patch met response criteria a...
DBV Technologies annonce des résultats préliminaires positifs dans l’étude de phase 3 VITESSE sur le patch VIASKIN® Peanut chez les enfants âgés de 4 à 7 ans allergiques à l’arachide Châtillon, France, le 16 décembre 2025 DBV Technologies annonce des résultats préliminaires positifs dans l’étude de phase 3 VITESSE sur le patch VIASKIN® Peanut chez les enfants âgés de 4 à 7 ans allergiques à l’arachide VITESSE a atteint son critère d’évaluation principal : la limite inférieure de l’intervalle de confiance à 95 % (IC) à savoir la différence entre les taux de réponse des groupes actif et pl...
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of November 30, 2025 Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of November 30, 2025 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights11/30/2025 200,777,718 Total gross of voting rights: 200,777,718 Total net* of voting rights: 200,667,869 * Net total = total number of voting rights at...
Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 novembre 2025 Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 novembre 2025 (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : NYSE Euronext Paris Code ISIN : FR 0010417345 Date Nombre totald’actionscomposant le capital socialNombre totalde droits de vote30/11/2025 200.777.718 Total brut des droits de vote : 200.777.718 Total net* des droits de vote : 200.667.869 *Total net = nombre t...
In today's Morning Views publication we comment on developments of the following high yield issuers: Eircom, EVOCA, Altice France (SFR), Stada, TGS ASA, EnQuest Plc, Crown Holdings, Alain Afflelou, Manuchar, Asmodee, Novelis, Arxada, Ahlstrom, AMS Osram, Ardagh Metal Beverage Packaging, Odigeo, Motel One
DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years Châtillon, France, November 11, 2025 DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years Company remains on track for VITESSE topline data in Q4 of this year DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced that the l...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.